Biomarker-based Alzheimer's Disease Cohort Study (BASIC)

Condition(s) studied

Investigational drug(s) / intervention(s)

None-placebo: This study is an observational study, and no interventions will be implemented.

Study summary

This study adopts a prospective cohort design, constructing a single-center cohort by recruiting patients with Alzheimer's disease (AD) who are positive for AD biomarkers. First, the investigators aim to establish a cohort of AD patients with positive biomarkers, thereby reserving suitable patient resources for future AD-related clinical trials. Second, based on the established cohort, the investigators will explore the associations between AD-related biomarkers and clinical manifestations among the elderly population in China, and identify potential risk factors influencing the progression of AD. Third, according to the identified risk factors for AD progression, the investigators will construct a risk early warning model for the progression rate of AD based on biomarkers, in order to achieve early identification and precise prevention and control of the progression risk of AD.

Eligibility

Primary outcome measure(s)

• The event of conversion from mild cognitive impairment to dementia within three years. — Assessments will be conducted every 6 months to 1 year upto 15 years for each participant.
  The event of conversion from mild cognitive impairment to dementia within three years. Cognitive status will be assessed using Clinical Dementia Rating scale-Global Score (CDR-GS): mild cognitive impairment: CDR-GS = 0.5; dementia: CDR-GS \> 0.5.

Trial sites (1)

More Xuanwu Hospital, Beijing trials in China

Other trials for the same condition